TY - JOUR
T1 - The multi-faceted assessment of independence in patients with rheumatoid arthritis
T2 - Preliminary validation from the ATTAIN study
AU - Hassett, Afton L.
AU - Li, Tracy
AU - Buyske, Steven
AU - Savage, Shantal V.
AU - Gignac, Monique A.M.
N1 - Funding Information:
Declaration of interest: This study was supported by Bristol-Myers Squibb, where ALH acts as a consultant. We thank Dr. Ross Maclean from the Department of Global Epidemiology and Outcomes Research at Bristol-Myers Squibb for his review of this manuscript and encouragement. No outside editing or writing assistance was used. The Clinical Trial Registry number for the ATTAIN trail is NCT00124982.
PY - 2008/5
Y1 - 2008/5
N2 - Objective: To consider the feasibility of assessing multiple facets of independence in rheumatoid arthritis (RA) using a measure developed from existing items and examining its face validity, construct validity and responsiveness to change. Methods: The ATTAIN (Abatacept Trial in Treatment of Anti-tumor necrosis factor [TNF] Inadequate responders) database was used. Patients with RA were randomized 2:1, abatacept (n = 258) and placebo (n = 133). A multi-faceted scale to measure physical and psychosocial independence was constructed using items from the Health Assessment Questionnaire (HAQ) and Short Form 36 Health Survey (SF-36). Questions assessing activity limitations and need for outside caregiver help were also examined. Interviews with 20 RA patients assessed face validity. Results: Item Response Theory analysis yielded two traits - 'Psychosocial Independence', derived from the number of days with activity limitations plus the Role Emotional, Social Functioning and Role Physical subscale items from the SF-36; and 'Physical Independence', derived from 15 HAQ items assessing need for help from another. The two traits showed no significant differential item functioning for age or gender and demonstrated good face validity. Changes over 169 days on Psychosocial Independence were greater (mean 0.46 units, 95% confidence interval [CI]: 0.17-0.75) for the abatacept group than for placebo (p = 0.002). Changes in Physical Independence were greater (mean 0.59 units, 95% CI: 0.35-0.82) for the abatacept group than for placebo (p < 0.001). Conclusions: The multi-faceted assessment of independence in RA based on items from commonly used instruments is feasible suggesting promise for evaluating independence in future clinical trials. This approach demonstrated good face and construct validity and responsiveness in RA patients who had previously failed anti-TNF therapy. However, we caution against an interpretation that these data suggest that abatacept improves independence because the component parts of this assessment came from instruments used in the ATTAIN trial where data had been previously analyzed.
AB - Objective: To consider the feasibility of assessing multiple facets of independence in rheumatoid arthritis (RA) using a measure developed from existing items and examining its face validity, construct validity and responsiveness to change. Methods: The ATTAIN (Abatacept Trial in Treatment of Anti-tumor necrosis factor [TNF] Inadequate responders) database was used. Patients with RA were randomized 2:1, abatacept (n = 258) and placebo (n = 133). A multi-faceted scale to measure physical and psychosocial independence was constructed using items from the Health Assessment Questionnaire (HAQ) and Short Form 36 Health Survey (SF-36). Questions assessing activity limitations and need for outside caregiver help were also examined. Interviews with 20 RA patients assessed face validity. Results: Item Response Theory analysis yielded two traits - 'Psychosocial Independence', derived from the number of days with activity limitations plus the Role Emotional, Social Functioning and Role Physical subscale items from the SF-36; and 'Physical Independence', derived from 15 HAQ items assessing need for help from another. The two traits showed no significant differential item functioning for age or gender and demonstrated good face validity. Changes over 169 days on Psychosocial Independence were greater (mean 0.46 units, 95% confidence interval [CI]: 0.17-0.75) for the abatacept group than for placebo (p = 0.002). Changes in Physical Independence were greater (mean 0.59 units, 95% CI: 0.35-0.82) for the abatacept group than for placebo (p < 0.001). Conclusions: The multi-faceted assessment of independence in RA based on items from commonly used instruments is feasible suggesting promise for evaluating independence in future clinical trials. This approach demonstrated good face and construct validity and responsiveness in RA patients who had previously failed anti-TNF therapy. However, we caution against an interpretation that these data suggest that abatacept improves independence because the component parts of this assessment came from instruments used in the ATTAIN trial where data had been previously analyzed.
KW - Abatacept
KW - Disability
KW - Independence
KW - Outcome measures
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=44349121149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44349121149&partnerID=8YFLogxK
U2 - 10.1185/030079908X297376
DO - 10.1185/030079908X297376
M3 - Article
C2 - 18402714
AN - SCOPUS:44349121149
SN - 0300-7995
VL - 24
SP - 1443
EP - 1453
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 5
ER -